AI app reveals your biological age – and how to slow it down

Only as old as you feel … or only as old as your Young.AI app tells you?

We use our phones for just about everything these days; defying the aging process could be as straightforward as booking an Uber soon.

Longevity.Technology: The Hong Kong–based tech company Deep Longevity, which was recently acquired by Regent Pacific, has hit the headlines with its iPhone app Young.ai which aims to crunch biometric data via an easy-to-use smartphone app to interpret your biological age and provide you with a personalised Longevity strategy. Staying young? Now there’s an app for that …

Understanding and manipulating biological age unlocks the doors to far more therapies than just reading a chronological age from a data record. Biological age is calculated from health, lifestyle choices, genetic factors and accumulated damage; different organs age at different rates.

The Young.AI app, which is scheduled to debut on Apple’s app store on 29 September (an Android version is in the pipeline), will use a variety of deep aging clocks to calculate the user’s biological age, including blood test data, medical history, biomarkers, selfies and metrics from wearable fitness trackers like FitBit and Apple’s iWatch.

Once all the data is inputted, the app makes personalised suggestions that could slow, halt or even reverse the aging process.

Deep generative reinforcement learning is used by Deep Longevity, according to Founder and Chief Longevity Officer Alex Zhavoronkov, to: “track all the minute changes that transpire during aging (and then later manifest into diseases) very, very early and at many, many levels, so that we can identify longevity bottlenecks and we can identify various areas where we can intervene.”

Deep Longevity’s typical personalised report (from an earlier release).

Young.AI is, says Zhavoronkov: “It’s a new field of AI-guided longevity medicine … focused on bringing you a little bit back – maybe a lot back – but initially … closer to the age of your optimal performance, which for humans is usually anywhere from 20 to 40.

“After that, unfortunately, we have a declining path. The idea is to use AI on every level to identify interventions and modifications that bring you back, from voice to pictures to psychology to transcriptomic level, proteomic level, ECG – anything! All things are connected.”

Longevity Technology Deep Aging Clock
Prospective Applications of Deep Aging Clocks in the Pharmaceutical and Biotechnology Industries. Source: Trends in Pharmacological Sciences

“Here we are executing on the vision of Dr Alex Zhavoronkov, the original inventor of deep aging clocks to provide the most advanced research tools in the hands of everyone on the planet without any biases towards social status, race, or gender to help optimize for much longer and healthier lives. With the launch of the integrated app and web system, we are establishing the foundation for the longevity ecosystem designed to produce quantifiable results and help extend human life and performance”, said Jamie Gibson, the CEO of Regent Pacific.

Image by Dariusz Sankowski from Pixabay

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...